Christopher A. Rhodes

Dr. Chris Rhodes is CEO and founder of Drug Delivery Experts.

Dr. Rhodes is a pharmaceutical scientist with over 25 years of experience in developing complex formulations and delivery systems including long-acting injectables (PLGA (Poly (lactic-co-glycolic acid) and non-PLGA systems), formulations for peptides, proteins, antibodies, oligonucleotides, and small molecules. He played a key role in the development of various commercial products including Byetta, Lusedra, Bydureon (PLGA microspheres), Myalept, and Afrezza, and was an R&D leader at Amydis Diagnostics, SKS Ocular (PLGA microfabrication platform), Amylin, Guilford (Gliadel wafer PLGA microsphere, and polyphosphoester polymer platform), and Mannkind.

Dr Rhodes was Drug Development Team Leader for a propofol prodrug and an NCE for peripheral neuropathy at Guilford. He led translational research on delivery systems for exenatide, including nasal, pulmonary, and oral administration, as well as transdermal microporation technologies, evaluating several delivery systems in clinical studies.

Dr Rhodes is a founder of Sensulin, CASS Pharmaceuticals, and Baywind Bioventures, companies developing drug-delivery-enabled pharmaceutical assets.

He has a PhD in Chemistry (UCLA), a BS in cChemistry (NYU), and was a postdoctoral fellow at Yale.